Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yanan Zheng

Showing results (101-110 of 121) with videos related to

Pageof 13
Sort By:
Clinical Pharmacology and Therapeutics|December 16, 2017
Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease StatusPaul G Baverel, Vincent F S Dubois, Chao Yu Jin, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|December 24, 2023
Oncological outcomes of conversion therapy in gastric cancer patients with peritoneal metastasis: a large-scale retrospective cohort studyZhongyin Yang, Sheng Lu, Min Shi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2020
Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trialYanan Zheng, Xiao Yang, Chao Yan, et al.
The Journal of Infectious Diseases|April 3, 2025
Lenacapavir Plus Two Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or ZinlirvimabJoseph J Eron, Paul P Cook, Megha L Mehrotra, et al.
British Journal of Clinical Pharmacology|December 1, 2022
Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearanceMichael Hwang, Yen Lin Chia, Yanan Zheng, et al.
American Journal of Translational Research|April 12, 2021
Prediction model of objective response after neoadjuvant chemotherapy in patients with locally advanced gastric cancerWei Xu, Zhiyuan Fan, Lingquan Wang, et al.
Frontiers in Oncology|May 3, 2021
Prediction Model of Tumor Regression Grade for Advanced Gastric Cancer After Preoperative ChemotherapyWei Xu, Qianchen Ma, Lingquan Wang, et al.
Clinical Lung Cancer|July 23, 2019
Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer PatientsSriram Sridhar, Luis Paz-Ares, Hao Liu, et al.
Frontiers in Oncology|September 20, 2021
Is D2 Lymphadenectomy Alone Suitable for Gastric Cancer With Bulky N2 and/or Para-Aortic Lymph Node Metastases After Preoperative Chemotherapy?Wei Xu, Wentao Liu, Lingquan Wang, et al.
Frontiers in Oncology|September 9, 2021
Neoadjuvant Chemotherapy <i>Versus</i> Direct Surgery for Locally Advanced Gastric Cancer With Serosal Invasion (cT4NxM0): A Propensity Score-Matched AnalysisWei Xu, Lingquan Wang, Chao Yan, et al.
Pageof 13

Showing results (101-110 of 121) with videos related to

Sort By:
Pageof 13
Clinical Pharmacology and Therapeutics|December 16, 2017
Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease StatusPaul G Baverel, Vincent F S Dubois, Chao Yu Jin, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|December 24, 2023
Oncological outcomes of conversion therapy in gastric cancer patients with peritoneal metastasis: a large-scale retrospective cohort studyZhongyin Yang, Sheng Lu, Min Shi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2020
Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trialYanan Zheng, Xiao Yang, Chao Yan, et al.
The Journal of Infectious Diseases|April 3, 2025
Lenacapavir Plus Two Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or ZinlirvimabJoseph J Eron, Paul P Cook, Megha L Mehrotra, et al.
British Journal of Clinical Pharmacology|December 1, 2022
Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearanceMichael Hwang, Yen Lin Chia, Yanan Zheng, et al.
American Journal of Translational Research|April 12, 2021
Prediction model of objective response after neoadjuvant chemotherapy in patients with locally advanced gastric cancerWei Xu, Zhiyuan Fan, Lingquan Wang, et al.
Frontiers in Oncology|May 3, 2021
Prediction Model of Tumor Regression Grade for Advanced Gastric Cancer After Preoperative ChemotherapyWei Xu, Qianchen Ma, Lingquan Wang, et al.
Clinical Lung Cancer|July 23, 2019
Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer PatientsSriram Sridhar, Luis Paz-Ares, Hao Liu, et al.
Frontiers in Oncology|September 20, 2021
Is D2 Lymphadenectomy Alone Suitable for Gastric Cancer With Bulky N2 and/or Para-Aortic Lymph Node Metastases After Preoperative Chemotherapy?Wei Xu, Wentao Liu, Lingquan Wang, et al.
Frontiers in Oncology|September 9, 2021
Neoadjuvant Chemotherapy <i>Versus</i> Direct Surgery for Locally Advanced Gastric Cancer With Serosal Invasion (cT4NxM0): A Propensity Score-Matched AnalysisWei Xu, Lingquan Wang, Chao Yan, et al.
Pageof 13